Advertisement

Topics

FDA green lights first treatment for chronic GvHD

04:44 EDT 3 Aug 2017 | PharmaTimes

The US Food and Drug Administration has expanded the scope of Johnson & Johnson/AbbVie’s Imbruvica to include the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments, marking the first therapy specifically approved for the condition in the US.

Original Article: FDA green lights first treatment for chronic GvHD

NEXT ARTICLE

More From BioPortfolio on "FDA green lights first treatment for chronic GvHD"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...